Protalix BioTherapeutics (PLX) Income from Continuing Operations (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Income from Continuing Operations of 18388000.0 for Q1 2026, up 608.1% year-over-year from 2596822.45 in Q1 2025, and up 613.06% quarter-over-quarter from 3584000.0 in Q4 2025.
Protalix BioTherapeutics (PLX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 18388000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 608.1% year-over-year to 18388000.0; the TTM figure through Mar 2026 stood at 17613000.0 (up 108.29% YoY), while the FY2025 annual figure was 4684000.0, down 162.62% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 18388000.0, up from 3584000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 18388000.0 in Q1 2026, with the low at 20124000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 2286000.0 (2022), against an average of 107117.65.
- The sharpest annual moves came in 2023 and 2026: Income from Continuing Operations sank 526.92% in 2023, then surged 608.1% in 2026.
- Protalix BioTherapeutics' Income from Continuing Operations stood at 3210000.0 in 2022, then tumbled by 526.92% to 20124000.0 in 2023, then surged by 153.7% to 10806000.0 in 2024, then tumbled by 133.17% to 3584000.0 in 2025, then soared by 613.06% to 18388000.0 in 2026.
- Business Quant data shows PLX's Income from Continuing Operations at 18388000.0 in Q1 2026, 3584000.0 in Q4 2025, and 2414000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | 3.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.78 Mn |
| Mar 31, 2026 | 18.39 Mn |
| Dec 31, 2025 | -3.58 Mn |
| Sep 30, 2025 | 2.41 Mn |
| Jun 30, 2025 | 395,000.00 |
| Mar 31, 2025 | -3.62 Mn |
| Dec 31, 2024 | 10.81 Mn |
| Sep 30, 2024 | 3.47 Mn |
| Jun 30, 2024 | -2.20 Mn |
| Mar 31, 2024 | -4.60 Mn |
| Dec 31, 2023 | -20.12 Mn |
| Sep 30, 2023 | -1.85 Mn |
| Jun 30, 2023 | 16.21 Mn |
| Mar 31, 2023 | -3.13 Mn |
| Dec 31, 2022 | -3.21 Mn |
| Sep 30, 2022 | -3.57 Mn |
| Jun 30, 2022 | -5.33 Mn |
| Mar 31, 2022 | -2.29 Mn |
| Dec 31, 2021 | -6.61 Mn |
| Sep 30, 2021 | -4.30 Mn |